Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life.
Clin Exp Rheumatol
; 34(3 Suppl 97): S54-9, 2016.
Article
en En
| MEDLINE
| ID: mdl-27049404
ABSTRACT
OBJECTIVES:
To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy.METHODS:
In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed.RESULTS:
Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demonstrated by SF-36, study patients' baseline HRQOL was significantly impaired compared with age- and sex-matched US norms. At month 24, mean changes from baseline of SF-36 physical component score tended to be better for the rituximab group (+3.95 points, p=0.067) whereas mean changes from baseline of the SF-36 mental component score were significantly better for the azathioprine group (+4.23 points, p=0.041).CONCLUSIONS:
Azathioprine-treated patients' for AAV maintenance therapy showed a decline in physical abilities when compared to RTX at M24 in the MAINRITSAN trial. TRIAL REGISTRATION ClinicalTrials.gov, http//clinicaltrials.gov/, NCT00748644.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Azatioprina
/
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos
/
Rituximab
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Idioma:
En
Revista:
Clin Exp Rheumatol
Año:
2016
Tipo del documento:
Article